File Download
  • No File Attached
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: [(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?
  • Basic View
  • Metadata View
  • XML View
Title[(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?
 
AuthorsHo, CL2 1
Cheung, MK2 1
Chen, S2 1
Cheung, TT2 1
Leung, YL2 1
Cheng, KC2 1
Yeung, WD2 1
 
Issue Date2012
 
PublisherBC Decker Inc.
 
CitationMolecular Imaging, 2012, v. 11 n. 3, p. 229-239 [How to Cite?]
DOI: http://dx.doi.org/10.2310/7290.2011.00043
 
Abstract[11C]Acetate (ACT) positron emission tomography/computed tomography (PET/CT) is useful in the detection of hepatocellular carcinoma (HCC). This study aimed to evaluate whether [18F]fluoroacetate (FAC) could be an alternative analogue of [11C]ACT for the diagnosis of HCC. [18F]FAC was synthesized using the precursor t-butyl 2-(methanesulfonyloxy)ethanoate. Five volunteer patients with known HCC were recruited after consent. Whole-body [18F]FAC PET/CT was performed at 20 minutes and 1 hour postinjection and compared to [11C]ACT PET/CT at 20 minutes postinjection to assess biodistribution and tumor uptake characteristics. Qualitative and semiquantitative analyses were performed with statistical correlations on the physiologic organs of accumulation and HCC lesions for both tracers. [18F]FAC was obtained with 99% radiochemical purity, and the reaction yield was 16.0% with 1-hour synthesis time. The biodistribution of [18F]FAC on PET/CT was significantly different from that of [11C]ACT (p < .05) by the lack of preferential uptake in any specific organ, particularly the pancreas, resembling the pattern of blood-pool retention although partly metabolized via the bowel. There was no significant defluorination, and none of the [11C]ACT-avid HCC lesions showed increased [18F]FAC activity. These were different from the results reported on other species. [18F]FAC may not be a potential alternative tracer for [11C]ACT in PET/CT evaluation of HCC in human subjects.
 
ISSN1535-3508
2012 Impact Factor: 3.408
2012 SCImago Journal Rankings: 0.938
 
DOIhttp://dx.doi.org/10.2310/7290.2011.00043
 
DC FieldValue
dc.contributor.authorHo, CL
 
dc.contributor.authorCheung, MK
 
dc.contributor.authorChen, S
 
dc.contributor.authorCheung, TT
 
dc.contributor.authorLeung, YL
 
dc.contributor.authorCheng, KC
 
dc.contributor.authorYeung, WD
 
dc.date.accessioned2012-02-03T06:15:05Z
 
dc.date.available2012-02-03T06:15:05Z
 
dc.date.issued2012
 
dc.description.abstract[11C]Acetate (ACT) positron emission tomography/computed tomography (PET/CT) is useful in the detection of hepatocellular carcinoma (HCC). This study aimed to evaluate whether [18F]fluoroacetate (FAC) could be an alternative analogue of [11C]ACT for the diagnosis of HCC. [18F]FAC was synthesized using the precursor t-butyl 2-(methanesulfonyloxy)ethanoate. Five volunteer patients with known HCC were recruited after consent. Whole-body [18F]FAC PET/CT was performed at 20 minutes and 1 hour postinjection and compared to [11C]ACT PET/CT at 20 minutes postinjection to assess biodistribution and tumor uptake characteristics. Qualitative and semiquantitative analyses were performed with statistical correlations on the physiologic organs of accumulation and HCC lesions for both tracers. [18F]FAC was obtained with 99% radiochemical purity, and the reaction yield was 16.0% with 1-hour synthesis time. The biodistribution of [18F]FAC on PET/CT was significantly different from that of [11C]ACT (p < .05) by the lack of preferential uptake in any specific organ, particularly the pancreas, resembling the pattern of blood-pool retention although partly metabolized via the bowel. There was no significant defluorination, and none of the [11C]ACT-avid HCC lesions showed increased [18F]FAC activity. These were different from the results reported on other species. [18F]FAC may not be a potential alternative tracer for [11C]ACT in PET/CT evaluation of HCC in human subjects.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationMolecular Imaging, 2012, v. 11 n. 3, p. 229-239 [How to Cite?]
DOI: http://dx.doi.org/10.2310/7290.2011.00043
 
dc.identifier.doihttp://dx.doi.org/10.2310/7290.2011.00043
 
dc.identifier.epage239
 
dc.identifier.hkuros198329
 
dc.identifier.issn1535-3508
2012 Impact Factor: 3.408
2012 SCImago Journal Rankings: 0.938
 
dc.identifier.issue3
 
dc.identifier.pmid22554487
 
dc.identifier.scopuseid_2-s2.0-84862661268
 
dc.identifier.spage229
 
dc.identifier.urihttp://hdl.handle.net/10722/144590
 
dc.identifier.volume11
 
dc.languageeng
 
dc.publisherBC Decker Inc.
 
dc.publisher.placeCanada
 
dc.relation.ispartofMolecular Imaging
 
dc.subject.meshCarcinoma, Hepatocellular - pathology - radionuclide imaging
 
dc.subject.meshFluorine Radioisotopes - diagnostic use - pharmacokinetics
 
dc.subject.meshLiver Neoplasms - pathology - radionuclide imaging
 
dc.subject.meshNeoplasm Metastasis - radionuclide imaging
 
dc.subject.meshPositron-Emission Tomography and Computed Tomography - methods
 
dc.title[(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Ho, CL</contributor.author>
<contributor.author>Cheung, MK</contributor.author>
<contributor.author>Chen, S</contributor.author>
<contributor.author>Cheung, TT</contributor.author>
<contributor.author>Leung, YL</contributor.author>
<contributor.author>Cheng, KC</contributor.author>
<contributor.author>Yeung, WD</contributor.author>
<date.accessioned>2012-02-03T06:15:05Z</date.accessioned>
<date.available>2012-02-03T06:15:05Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Molecular Imaging, 2012, v. 11 n. 3, p. 229-239</identifier.citation>
<identifier.issn>1535-3508</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/144590</identifier.uri>
<description.abstract>[11C]Acetate (ACT) positron emission tomography/computed tomography (PET/CT) is useful in the detection of hepatocellular carcinoma (HCC). This study aimed to evaluate whether [18F]fluoroacetate (FAC) could be an alternative analogue of [11C]ACT for the diagnosis of HCC. [18F]FAC was synthesized using the precursor t-butyl 2-(methanesulfonyloxy)ethanoate. Five volunteer patients with known HCC were recruited after consent. Whole-body [18F]FAC PET/CT was performed at 20 minutes and 1 hour postinjection and compared to [11C]ACT PET/CT at 20 minutes postinjection to assess biodistribution and tumor uptake characteristics. Qualitative and semiquantitative analyses were performed with statistical correlations on the physiologic organs of accumulation and HCC lesions for both tracers. [18F]FAC was obtained with 99% radiochemical purity, and the reaction yield was 16.0% with 1-hour synthesis time. The biodistribution of [18F]FAC on PET/CT was significantly different from that of [11C]ACT (p &lt; .05) by the lack of preferential uptake in any specific organ, particularly the pancreas, resembling the pattern of blood-pool retention although partly metabolized via the bowel. There was no significant defluorination, and none of the [11C]ACT-avid HCC lesions showed increased [18F]FAC activity. These were different from the results reported on other species. [18F]FAC may not be a potential alternative tracer for [11C]ACT in PET/CT evaluation of HCC in human subjects.</description.abstract>
<language>eng</language>
<publisher>BC Decker Inc.</publisher>
<relation.ispartof>Molecular Imaging</relation.ispartof>
<subject.mesh>Carcinoma, Hepatocellular - pathology - radionuclide imaging</subject.mesh>
<subject.mesh>Fluorine Radioisotopes - diagnostic use - pharmacokinetics</subject.mesh>
<subject.mesh>Liver Neoplasms - pathology - radionuclide imaging</subject.mesh>
<subject.mesh>Neoplasm Metastasis - radionuclide imaging</subject.mesh>
<subject.mesh>Positron-Emission Tomography and Computed Tomography - methods</subject.mesh>
<title>[(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.2310/7290.2011.00043</identifier.doi>
<identifier.pmid>22554487</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84862661268</identifier.scopus>
<identifier.hkuros>198329</identifier.hkuros>
<identifier.volume>11</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>229</identifier.spage>
<identifier.epage>239</identifier.epage>
<publisher.place>Canada</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Hong Kong Sanatorium and Hospital